Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging

Chronic Kidney Disease in Diabetes

(2018) Philip McFarlane et al.   Canadian Journal of Diabetes

Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New

(2018) Ronald M. Goldenberg et al.   Canadian Journal of Diabetes

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

(2018) Petter Bjornstad et al.   DIABETES CARE

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors

(2018) Hiddo J.L. Heerspink et al.   KIDNEY INTERNATIONAL

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

(2018) David Z.I. Cherney et al.   KIDNEY INTERNATIONAL

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

(2016) Volker Vallon et al.   DIABETOLOGIA

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

(2016) Hiddo J. L. Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glomerular haemodynamic profile of patients with Type 1 diabetes compared with healthy control subjects

(2015) M. Škrtić et al.   DIABETIC MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

(2014) Marko Škrtić et al.   DIABETOLOGIA

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

(2014) Atsuo Tahara et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Maintenance of Endothelial Guanosine Triphosphate Cyclohydrolase I Ameliorates Diabetic Nephropathy

(2013) K. Kidokoro et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus

(2012) David Z. I. Cherney et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes

(2012) P. Ruggenenti et al.   DIABETES CARE

Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats

(2010) A. Kuwabara et al.   DIABETOLOGIA

The clinical significance of hyperfiltration in diabetes

(2010) G. Jerums et al.   DIABETOLOGIA

In VivoVisualization of Glomerular Microcirculation and Hyperfiltration in Streptozotocin-Induced Diabetic Rats

(2010) MINORU SATOH et al.   MICROCIRCULATION